![]() |
市場調查報告書
商品編碼
1930078
睡眠呼吸中止症治療設備市場規模、佔有率、成長及全球產業分析:按類型、應用和地區劃分的洞察,2026-2034 年Sleep Apnea Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
由於睡眠呼吸障礙盛行率的上升以及人們對早期診斷和治療意識的提高,全球睡眠呼吸中止症治療設備市場正經歷顯著增長。睡眠呼吸中止症是一種嚴重的睡眠障礙,其特徵是睡眠期間呼吸反覆中斷,導致大腦和其他器官的氧氣供應減少。這種疾病在老年人和患有肥胖、糖尿病、高血壓和心血管疾病等合併症的人中更為常見。根據 Fortune Business Insights 的一項研究,2025 年全球睡眠呼吸中止症治療設備市場價值為 103 億美元。預計該市場將從 2026 年的 110 億美元成長到 2034 年的 228.7 億美元,預測期內複合年增長率 (CAGR) 為 9.59%。
到 2025 年,北美將主導全球市場,佔 49.55% 的市場。這主要歸功於阻塞性睡眠呼吸中止症 (OSA) 的高發病率、有利的報銷政策以及對技術先進的睡眠呼吸中止症治療設備的廣泛應用。
市場驅動因素
睡眠呼吸中止症治療設備市場的主要成長驅動因素是全球阻塞性睡眠呼吸中止症 (OSA) 盛行率的不斷上升。根據美國國家生物技術資訊中心 (NCBI) 發布的數據,全球約有 9.36 億人患有輕度至重度阻塞性睡眠呼吸中止症 (OSA),其中 4.25 億人患有中度至重度 OSA。久坐的生活方式、肥胖、睡眠模式不良和壓力增加是導致疾病發生率上升的主要因素。
此外,人口老化加劇和慢性病負擔加重也推動了 OSA 診斷和治療率的提高。美國國家睡眠基金會等機構所進行的提高公眾意識的活動和宣傳也促進了睡眠呼吸中止症早期診斷和治療設備的普及。新冠疫情加劇了與壓力相關的睡眠障礙,也推動了疫情期間及之後對診斷和治療設備的需求成長。
市場趨勢
影響市場的關鍵趨勢是技術先進、人性化的設備的日益普及。口腔矯正器,例如下顎前移矯正器 (MAD),因其舒適性、便攜性和非侵入性而越來越受歡迎。 2024年2月,美國FDA批准了一種新型下顎復位裝置AIO BREATHE,反映了口腔內睡眠呼吸中止症治療方案領域技術創新的不斷進步。
另一個重要趨勢是便攜式、經濟實惠的診斷設備(例如活動記錄器和家庭睡眠測試工具)的使用日益增多。這些設備因其價格實惠且適合家庭診斷而備受關注,從而推動了睡眠呼吸中止症管理模式轉向分散式。
市場限制因子
儘管市場成長前景強勁,但睡眠呼吸中止症治療設備的高昂成本仍是市場面臨的挑戰。持續性呼吸道正壓通氣(CPAP)設備廣泛用於治療阻塞性睡眠呼吸中止症(OSA),但價格昂貴,在美國通常售價在600至800美元之間,給沒有醫療保險的患者帶來了沉重的負擔。發展中國家有限的保險覆蓋範圍和高昂的自付費用進一步限制了設備的普及,阻礙了市場成長。
依設備類型劃分,市場分為治療設備和診斷設備。預計到2026年,治療設備細分市場將以63.36%的市場佔有率佔主導地位,這主要得益於治療率的提高以及CPAP設備、口腔設備及面罩的廣泛應用。診斷設備也持續成長,這主要歸功於未確診患者的數量以及人們對睡眠障礙診斷意識的提高。
依最終使用者劃分,市場分為家庭照護及其他場所及睡眠實驗室診所。預計到2026年,家庭護理及其他場所細分市場將以53.83%的市場佔有率佔主導地位,這主要得益於人們對家庭治療的偏好日益增強以及便攜式診斷設備的出現。睡眠實驗室診所預計也將穩定成長,這主要得益於患者數量的增加以及熟練睡眠技師的普及。
北美將引領市場,預計到2025年市場規模將達到51.1億美元,其中美國市場預計到2026年將達到51億美元。
由於睡眠呼吸中止症的盛行率和認知度不斷提高,亞太地區預計將實現最高的複合年增長率。到2026年,日本市場預計將達到4.7億美元,中國市場預計將達到6.2億美元,印度市場預計將達到1.9億美元。
歐洲市場預計將穩定成長,預計到2026年,英國市場將達到4.7億美元,德國市場將達到7.3億美元,主要得益於老年族群較高的發生率。
The global sleep apnea devices market is witnessing substantial growth due to the rising prevalence of sleep-related breathing disorders and increasing awareness regarding early diagnosis and treatment. Sleep apnea is a serious sleep disorder characterized by repeated interruptions in breathing during sleep, leading to reduced oxygen supply to the brain and other organs. This condition is more common among elderly individuals and patients suffering from comorbidities such as obesity, diabetes, hypertension, and cardiovascular disorders. According to Fortune Business Insights, the global sleep apnea devices market size was valued at USD 10.30 billion in 2025. The market is projected to grow from USD 11.00 billion in 2026 to USD 22.87 billion by 2034, exhibiting a CAGR of 9.59% during the forecast period.
North America dominated the global market in 2025, accounting for a 49.55% market share, driven by a high prevalence of obstructive sleep apnea (OSA), favorable reimbursement policies, and strong adoption of technologically advanced sleep apnea devices.
Market Drivers
The primary growth driver for the sleep apnea devices market is the rising prevalence of obstructive sleep apnea worldwide. According to data published by the National Center for Biotechnology Information (NCBI), approximately 936 million people globally suffer from mild to severe OSA, while 425 million people are affected by moderate to severe OSA. Sedentary lifestyles, obesity, poor sleep patterns, and increased stress levels are major contributors to the rising incidence of this condition.
In addition, the growing geriatric population and increasing burden of chronic diseases are leading to higher diagnosis and treatment rates. Awareness initiatives and campaigns by organizations such as the National Sleep Foundation are further encouraging early diagnosis and adoption of sleep apnea devices. The positive impact of COVID-19, which increased stress-related sleep disorders, also supported higher demand for diagnostic and therapeutic devices during and after the pandemic.
Market Trends
A key trend shaping the market is the growing adoption of technologically advanced and patient-friendly devices. Oral appliances such as mandibular advancement devices (MADs) are gaining popularity due to their comfort, portability, and non-invasive nature. In February 2024, the U.S. FDA approved AIO BREATHE, a new mandibular repositioning device, reflecting rising innovation in oral sleep apnea solutions.
Another significant trend is the increasing use of portable and cost-effective diagnostic devices, such as actigraphy systems and home sleep testing tools. These devices are gaining traction due to their affordability and suitability for home-based diagnosis, supporting the shift toward decentralized sleep apnea management.
Market Restraints
Despite strong growth prospects, the market faces challenges related to the high cost of sleep apnea devices. Continuous Positive Airway Pressure (CPAP) machines, which are widely used for OSA treatment, typically cost USD 600 to USD 800 in the U.S., making them expensive for uninsured patients. Limited reimbursement policies and high out-of-pocket expenses in developing countries further restrict device adoption, thereby hampering market growth.
By Device Type, the market is segmented into therapeutic devices and diagnostic devices. The therapeutic devices segment dominated the market with a 63.36% share in 2026, driven by increasing treatment rates and higher adoption of CPAP devices, oral appliances, and masks. Diagnostic devices are also witnessing growth due to the presence of a large undiagnosed population and increasing awareness regarding sleep disorder diagnosis.
By End User, the market is segmented into homecare & other settings and sleep laboratories & clinics. The homecare & other settings segment dominated with a 53.83% share in 2026, supported by the growing preference for home-based treatment and the launch of portable diagnostic devices. Sleep laboratories and clinics are also expected to grow steadily due to rising patient admissions and availability of skilled sleep technicians.
North America led the market, with a market size of USD 5.11 billion in 2025, and the U.S. market projected to reach USD 5.10 billion by 2026.
Asia Pacific is expected to register the fastest CAGR, driven by rising prevalence of sleep apnea and increasing awareness. By 2026, Japan is projected to reach USD 0.47 billion, China USD 0.62 billion, and India USD 0.19 billion.
Europe is projected to grow steadily, with the UK market reaching USD 0.47 billion and Germany USD 0.73 billion by 2026, supported by high prevalence among the geriatric population.
Competitive Landscape
The market is highly competitive, with ResMed holding a dominant position due to its strong product portfolio and continuous innovation. Other key players include Koninklijke Philips N.V., Fisher & Paykel Healthcare Limited, SomnoMed, Compumedics Limited, and Braebon Medical Corporation. These companies focus on product launches, FDA approvals, and strategic acquisitions to strengthen their market presence.
Conclusion
In conclusion, the global sleep apnea devices market is expected to grow significantly from USD 10.30 billion in 2025 to USD 22.87 billion by 2034, driven by rising prevalence of obstructive sleep apnea, growing awareness, technological advancements, and increasing preference for home-based care. Although high device costs and reimbursement limitations remain key challenges, continuous innovation, expanding diagnostic capabilities, and increasing healthcare investments are expected to sustain robust market growth throughout the forecast period.
Segmentation
By Device Type
By End User
By Geography